Immune characteristics of severe and critical COVID-19 patients

Dear Editor,

Recently, the novel coronavirus disease (COVID-19) has broken out worldwide, with rapid increase of infected patients. COVID-19 dominantly leads to pneumonia. Among these COVID-19 patients, some appears to be severe symptoms with acute respiratory distress syndrome, organ failure, and further present a poor outcome.

Previous studies have been reported that immune patterns are closely associated with disease progression of patients infected with other viruses. The correlation between immune signatures and out of severe and critical COVID-19 cases was not well illuminated. Therefore, we aimed to evaluate the correlation between immune characteristics, especially levels of lymphocytes and cytokines in peripheral blood, and clinical parameters in severe and critical COVID-19 patients, in order to find critical indicators of disease progression and to provide important guides for therapeutic strategy.

Thirty-six adult cases with severe and critical COVID-19 were enrolled. The disease outcome, immune patterns, microbiota infection, coagulation profile, and organ dysfunction biomarkers were analyzed and collected. This project was approved by the Ethics Committee of our hospital (No. 2020-KY-060), and all patients signed the informed consent.

We found that the cell numbers of lymphocytes in these patients were obviously decreased compared to that in healthy donors, including total lymphocytes, total T, CD4\(^+\) T, CD8\(^+\) T, B and NK cells (Fig. 1a), and the percentage of lymphocytes in COVID-19 patients was also significantly decreased except B cells (Supplementary Fig. S1a, b), with an increased ratio of CD4\(^+\)/CD8\(^+\) T cells (Supplementary Fig. S1c), suggesting that CD8\(^+\) T cell number was more decreased than CD4\(^+\) T cell number in these patients. Particularly and importantly, the mean value of only B cell number (150.05\(/\mu L\)) was within normal range (90-560)/\(\mu L\) (Fig. 1a). All these data indicate that lymphocytes are impaired in severe and critical COVID-19 patients, especially more impaired in CD8\(^+\) T cells than in CD4\(^+\) T cells, and little impaired in B cells, which results in the higher percentage of B cells.

Furthermore, the cytokine levels, including IL-2, IL-4, IL-6, IL-10, TNF-\(\alpha\), and IFN-\(\gamma\), were remarkably increased; especially IL-6 and IL-10 (Fig. 1a, Supplementary Fig. S2a). The results presented that the maximum values of IL-2, IL-4, IL-6, IL-10, TNF-\(\alpha\), and IFN-\(\gamma\) were 16.66, 16.87, >14031.14, 7451.48, 155.53, and 453.95 (pg/mL), respectively (Supplementary Fig. S2b). Moreover, the percentages of patients with IL-6 and IL-10 upregulation were 97.0% and 100.0%, respectively, which were significantly higher than that of patients with other cytokine upregulation (Supplementary Fig. S2b). In addition, the levels of IL-6 and IL-10 in critical COVID-19 patients were significantly higher than that in severe COVID-19 patients (Supplementary Fig. S2c). These findings demonstrate that cytokine level was elevated in severe and critical COVID-19 patients, particularly IL-6 and IL-10 were enormously increased.

To further evaluate the correlation between these immune parameters and clinical prognosis, we analyzed the overall survivals in patients with high and low levels of lymphocyte subpopulations and cytokines. We found that patients with high levels of total lymphocytes, total T, CD4\(^+\) T, CD8\(^+\) T, and NK cells had a good survival [cutoff value: total lymphocytes, 824.08; total T, 593; CD4\(^+\) T, 376; CD8\(^+\) T, 191; NK, 82.24 (\(\mu L\))] (Fig. 1b). Furthermore, patients with high levels of IL-6 and IL-10 had a poor overall survival [cutoff value: IL-6, 65.918; IL-10, 8.43 (pg/mL)] (Fig. 1b). Among these COVID-19 patients, the percentages of patients with high levels of lymphocytes, including total lymphocytes, total T, CD4\(^+\) T, CD8\(^+\) T, and NK cells, were obviously higher in all survivors than that in the non-survivors (Supplementary Fig. S3a), and there was an opposite result for B cells. Meanwhile, patients with low levels of IL-6 and IL-10 were basically live (Supplementary Fig. S3b). Through computed tomography (CT) imaging of one patient during the recovery, inflammation was markedly reduced, which accompanied by the increased levels of each lymphocyte subpopulations (Fig. 1c).

Furthermore, one non-survivor presented a severe inflammation by CT imaging with serious IL-6 and IL-10 production; however, in another survivor, IL-6 and IL-10 levels were significantly decreased with a relatively mild inflammation by CT imaging (Fig. 1d). Therefore, immune characteristics are closely associated with disease progression, which could be served as a potential biomarker for prognosis of severe and critical COVID-19 patients.

It has been shown that there is a close cross talk between immune homeostasis and gut microbiota on host in several diseases. So we further investigated the effect of lymphocytes on infection of microbiota in these COVID-19 patients, which could accelerate disease progression. (1,3)-\(\beta\)-D-glucan, a key structural component of fungus cell wall, in patients with low levels of lymphocytes, was significantly higher than that in patients with high level lymphocytes, excluded B cells (Fig. 1e). Most of the patients infected with microbiota had a lower level of lymphocytes, also excluded B cells (Fig. 1f). The special gut microbiota, which were infected in severe and critical COVID-19 patients, included baumanii, klebsiella pneumonia, enterobacter cloacae complex, stenotrophomonas maltophilia, candida famata, candida glabrata, candida albicans, enterococcus, burkholideria cepacia, pseudomonas aeruginosa, and saccharomyces cerevisiae (Supplementary Table S1). And baumanii was the most frequent microbiota that infected patients (Supplementary Table S1).

Collectively, low lymphocyte level in COVID-19 patients is closely associated with microbiota infection. Lastly, IL-6 level was closely correlated with D-Dimer and organ dysfunction biomarkers [liver: aspartate aminotransferase (AST), kidney: urea, heart: creatine kinase (CK) and lactate dehydrogenase (LDH)] (Fig. 1g). With IL-10 increase, \(\gamma\)-glutamyl trans peptidase (\(\gamma\)-GT) level (liver dysfunction) was obviously upregulated (Fig. 1g). The data demonstrate that elevated cytokine level is closely associated with severe syndromes of blood coagulation and multiple organs dysfunction.

In this study, severe and critical COVID-19 patients exhibit lymphopenia and high level of cytokines, especially impaired T cells, and increased IL-6 or IL-10, which are served as potential biomarkers.
for disease progression. Other studies also reported that lymphocyte deficiency or incapacity in COVID-19 patients promoted disease progression, and most of severe cases presented elevated levels of infection-related biomarkers and inflammatory cytokines. Low level of lymphocytes was closely related with microbiota infection in these patients, suggesting that impaired lymphocytes further induced microbiota infection to exacerbate disease progression, which could provide a guide for the antibiotic usage of severe and critical COVID-19 patients. 

Nevertheless, B cells exhibited a relatively opposite phenomenon from other lymphocytes, revealing that B cells are little impaired, even activated and amplified in partial patients, which could be the reactive activation of virus infection, or be the occurrence of B cell super antigen induced by novel coronavirus promotes immune resistance and suppression.

ACKNOWLEDGEMENTS
We thank all people including doctors, nurses, researchers, and technicians, et al. for the efforts to fight against COVID-19 in this study. This work was supported by grants from the Emergency Prevention and Control of COVID-19 Project of Henan Province (No. 201100310900), the National Natural Science Foundation of China (No. 91942314, U1804281, and 81602024).

AUTHOR CONTRIBUTIONS
LY, JG, LH, and HL analyzed the samples. LY, JG, ZZ, SJ, LX, and MY were responsible for data collection and analyses. LY and YZ wrote the manuscript with input from all other authors.
ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41392-020-00296-3) contains supplementary material, which is available to authorized users.

Competing interests: The authors declare no competing interests.

Li Yang1, Jianjun Gou2, Jianbo Gao3, Lan Huang1, Zhiqiang Zhu4,Shaofei Ji5, Hongchun Liu2, Lihua Xing6, Mengying Yao6 and Yi Zhang1
1Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China; 2Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China; 3Department of Radiology, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China; 4Department of Radiology, Orthopaedic Hospital of Zhengzhou City, 450052 Zhengzhou, Henan, China and 5Department of Respiratory, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China
Correspondence: Lihua Xing (xinglihua95088@163.com) or Mengying Yao (zdyfyricu@hotmail.com) or Yi Zhang (yizhang@zzu.edu.cn)

REFERENCES
1. Kandel, N. et al. Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries. Lancet 395, 1047–1053 (2020).
2. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020).
3. Reynard, S. et al. Immune parameters and outcomes during Ebola virus disease. JCI Insight 4, 125106 (2019).
4. Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sig. Transduct. Target Ther. 5, 33 (2020).
5. Qin, C. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 71, 762–768 (2020).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020